Prognosis for Gleason 3+4 Prostate Cancer with PSA 4 ng/mL
A patient with Gleason score 3+4 (Grade Group 2) prostate cancer and PSA of 4 ng/mL has an excellent prognosis, with approximately 92% 10-year prostate cancer-specific survival and represents favorable intermediate-risk disease. 1
Risk Stratification
This clinical presentation falls into the favorable intermediate-risk category according to NCCN guidelines, defined by:
- Gleason score 3+4 (primary pattern 3)
- PSA <10 ng/mL (yours is 4 ng/mL)
- Clinical stage ≤T2a 2
The distinction between Gleason 3+4 versus 4+3 is critical for prognosis. Gleason 3+4 disease has significantly better outcomes than Gleason 4+3, with 10-year prostate cancer-specific survival of 92.1% versus 76.5%, respectively 1. This difference persists even after curative therapy, where Gleason 4+3 patients have more than double the risk of prostate cancer-specific mortality (HR 2.80) compared to 3+4 patients 1.
Expected Outcomes
Pathologic Features at Surgery
If radical prostatectomy is performed, approximately:
- 66-75% will have organ-confined disease (pT2) with negative margins 3, 4
- 25% may harbor unfavorable disease features (≥pT3 or upgrade to ≥Gleason 4+3) 3
- 13% risk of Gleason score upgrade at final pathology 3
- 17% risk of downgrade to Gleason 6 3
Long-term Cancer Control
With a PSA of 4 ng/mL and Gleason 3+4:
- 5-year biochemical recurrence-free survival: approximately 80-81% after definitive treatment 5
- 10-year prostate cancer-specific survival: 92.1% 1
- Risk of systemic metastasis at 10 years: approximately 8% 1
Clinical Implications
Treatment Considerations
Active surveillance may be considered for select patients with favorable intermediate-risk Gleason 3+4 disease according to updated NCCN guidelines 2. However, clinical parameters alone have limited predictive accuracy for identifying which patients harbor more aggressive disease 3.
Predictors of higher-risk disease within this favorable category include:
- Higher PSA density (PSAD) - each unit increase confers OR 1.83 for upgrade 3
- Percentage of positive biopsy cores >50% (OR 1.57 for unfavorable disease) 3
- Greater percentage of core involvement 3
- Presence of perineural invasion (OR 1.89 for unfavorable disease) 3
- Older age 3, 4
Comparison to Other Risk Groups
To contextualize this prognosis:
- Gleason 6 disease: 98.4% 10-year cancer-specific survival 1
- Your Gleason 3+4: 92.1% 10-year cancer-specific survival 1
- Gleason 4+3: 76.5% 10-year cancer-specific survival 1
- Gleason 8-10: 69.9% 10-year cancer-specific survival 1
Important Caveats
Gleason pattern 4 contributes disproportionately to PSA and disease aggressiveness. Pattern 4 tissue produces 6-8 times more PSA per cubic centimeter than pattern 3, and 15 times more than benign tissue 6. Your low PSA of 4 ng/mL with Gleason 3+4 disease suggests a relatively small volume of pattern 4, which is prognostically favorable.
Genomic testing may refine risk assessment beyond clinical parameters alone. Among favorable intermediate-risk patients, genomic classifiers like Decipher can help distinguish those suitable for active surveillance versus those requiring definitive treatment 2. Approximately 38-50% of favorable intermediate-risk patients have high-risk genomic signatures 7.
The heterogeneity within intermediate-risk disease means that patients with multiple intermediate-risk factors (T2b-c, PSA 10-20 ng/mL, or Gleason 7) have worse outcomes than those with single factors 2. Your presentation with only one intermediate-risk factor (Gleason 3+4) and otherwise low-risk features (PSA 4 ng/mL, presumably ≤T2a) places you in the most favorable subset.